Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991008795) IMPROVED IONTOPHORETIC DELIVERY METHOD
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/008795 International Application No.: PCT/US1990/007273
Publication Date: 27.06.1991 International Filing Date: 10.12.1990
Chapter 2 Demand Filed: 03.07.1991
IPC:
A61K 9/00 (2006.01) ,A61N 1/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
N
ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
1
Electrotherapy; Circuits therefor
18
Applying electric currents by contact electrodes
20
continuous direct currents
30
Apparatus for iontophoresis or cataphoresis
Applicants:
ALZA CORPORATION [US/US]; 950 Page Mill Road Palo Alto, CA 94303-0802, US
Inventors:
HAAK, Ronald, P.; US
GYORY, J., Richard; US
YIEH, Jane; US
Agent:
MILLER, D., Byron ; Alza Corporation, A2W 950 Page Mill Road P.O. Box 10950 Palo Alto, CA 94303-0802, US
Priority Data:
452,13614.12.1989US
Title (EN) IMPROVED IONTOPHORETIC DELIVERY METHOD
(FR) PROCEDE AMELIORE D'ADMINISTRATION D'UN MEDICAMENT PAR IONTOPHORESE
Abstract:
(EN) An improved method for delivering a drug or beneficial agent transdermally to humans by iontophoresis is provided. The method includes selecting and iontophoretically delivering the drug through a skin site (11) which optimizes the transdermal delivery rate of the drug while minimizing inter-patient variability in skin resistance.
(FR) Le procédé amélioré décrit utilise l'iontophorèse pour administrer à un patient un médicament ou un agent bénéfique par voie transdermique. Ce procédé consiste à sélectionner et à administrer par iontophorèse le médicament à travers un site (11) de la peau choisi de façon à optimiser la vitesse de passage transdermique du médicament, tout en réduisant au minimum les variations de résistance de la peau dues à des facteurs propres au patient.
Designated States: AU, FI, JP, KR, NO
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1991069725